Healx

Healx

Private
Cambridge, EnglandHealthcare & Life Scienceshttps://www.healx.ai

Last Round

Series C

Aug 1, 2024

Total Funding Raised

$114.9M

Company Overview

Healx is a biotechnology company that utilizes artificial intelligence-driven drug discovery technology to develop treatments for rare diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Medical AI, ML Platforms, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

AI drug discoverydrug repurposingrare disease treatmentsdrug discovery platformAI biotechbiomedical knowledge graphindication expansionin silico drug discoverytech-enabled biotechpharmaceutical partnershipsdrug repositioningco-development agreementsdrug licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Healx Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Healx Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series CAug 1, 2024
Series BOct 16, 2019
Series AJul 26, 2018
SeedOct 4, 2016

Key People

Founding team and executive leadership

Tim Guilliams

Co-founder, CEO

Founding Team

Healx Investors

Notable investors and investment history

InvestorRounds
Amadeus Capital PartnersSeries A, Series B, Seed
o2h venturesSeries C
Intel CapitalSeries B
b2ventureSeries C, Series B
VU Venture PartnersSeries C
AtomicoSeries C, Series B
Global BrainSeries C, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 1, 2025

    Partnered with Vuja De Sciences to focus on oncology.

  • Jul 1, 2025

    Drug candidates have entered clinical trials, indicating a clinical-stage development.

Healx Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Healx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Healx's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, England
Employee Range64
Year Founded2014
Last FundingAug 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.